HER2+ Cancer – Patient Worthy

Phase 3 HERIZON-GEA-01 Analysis Strengthens Survival Evidence for Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer

Post author:Austin Newman
Post published:September 6, 2026
Post category:Gastroesophageal junction carcinoma

As reported on PharmaBiz, BeOne Medicines has reported positive results from the second interim analysis of the phase 3 HERIZON-GEA-01 trial, further supporting the use of zanidatamab (Ziihera)-containing regimens as…

EU Approves Enhertu Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

Post author:Austin Newman
Post published:September 4, 2026
Post category:Metastatic Breast Cancer

As reported on Business Wire, the European Commission has approved trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.…

EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer

Post author:Austin Newman
Post published:July 30, 2026
Post category:Breast Cancer

As reported on PharmaBiz, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation supporting approval of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate…

source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Post author:Rose Duesterwald
Post published:January 8, 2024
Post category:Cancer

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

HER2 Positive Cancer Treatment Moves Into Expansion Study

Post author:Kendall Mason
Post published:February 11, 2021
Post category:Cancer

Zymeworks Inc. has recently began enrollment for an expansion cohort of the Phase 1 trial of ZW49. ZW49 is an antibody-drug conjugate (ADC) that targets HER2 positive cancer cells. This…

Phase 3 HERIZON-GEA-01 Analysis Strengthens Survival Evidence for Zanidatamab-Based Regimens in HER2-Positive Gastroesophageal Cancer

EU Approves Enhertu Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

EMA Backs Enhertu Plus Pertuzumab as Potential New First-Line Standard for HER2-Positive Metastatic Breast Cancer

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

HER2 Positive Cancer Treatment Moves Into Expansion Study

Let’s Work Together!

Keep Up to Date

Learn More